Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:4:p22
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 4 (pt 22/22)
Character Range: 250078–251030

of vitamin D per recommended daily dose ; or
 (b) when included in Schedule 3.
VORAPAXAR.
VORASIDENIB.
VORETIGENE NEPARVOVEC.
VORICONAZOLE.
VORINOSTAT.
VORTIOXETINE.
VOSORITIDE.
VOXILAPREVIR.
VUTRISIRAN.
WARFARIN for therapeutic use.
XAMOTEROL.
XANTHINOL NICOTINATE.
XIMELAGATRAN.
XIPAMIDE.
XYLAZINE.
YOHIMBINE.
ZAFIRLUKAST.
ZALCITABINE.
ZALEPLON.
ZANAMIVIR.
ZANUBRUTINIB.
ZERANOL except when included in Schedule 6.
ZIDOVUDINE.
ZILPATEROL.
ZILUCOPLAN.
ZIMELDINE.
ZINC COMPOUNDS for human internal use except:
 (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or
 (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required advisory statements for medicine labels.
ZIPRASIDONE.
ZOLAZEPAM.
ZOLBETUXIMAB.
ZOLEDRONIC ACID.
ZOLMITRIPTAN except when included in Schedule 3.
ZOLPIDEM.
ZONISAMIDE.
ZOPICLONE.
ZOXAZOLAMINE.
ZUCLOPENTHIXOL.